New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2013
07:31 EDTNAVBNavidea granted FDA Fast Track Designation for Lymphoseek Injection
Navidea Biopharmaceuticals announced that the US Food and Drug Administration has granted Fast Track designation to Lymphoseek Injection for sentinel lymph node detection in patients with head and neck cancer. Navidea intends to file the supplemental New Drug Application for Lymphoseek before year-end. Lymphoseek was approved by the FDA in March for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma. William J Regan, Navidea Senior Vice President for Global Regulatory Strategy, says “After filing the sNDA, we look forward to working closely with the FDA to bring to market as quickly as possible an expanded label for Lymphoseek and what will be the first agent indicated in sentinel lymph node detection."
News For NAVB From The Last 14 Days
Check below for free stories on NAVB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
17:33 EDTNAVBNavidea provides update on Lymphoseek programs
Subscribe for More Information
April 10, 2014
07:34 EDTNAVBNavidea presents Manocept platform study findings
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use